Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia

Publisher： Bentham Science Publishers

E-ISSN： 1875-6220|11|2|145-153

ISSN： 1570-1638

Source： Current Drug Discovery Technologies, Vol.11, Iss.2, 2014-06, pp. : 145-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors

By  

Current Pharmacogenomics, Vol. 5, Iss. 3, 2007-09 ,pp. : 201-213

Bentham Science Publishers

Access to resources Recommend Favorite

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

By Radich Jerald P.   Oehler Vivian  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 5, 2007-05 ,pp. : 497-504

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms

By  

Current Medicinal Chemistry, Vol. 17, Iss. 13, 2010-05 ,pp. : 1220-1245

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia

By Mughal Tariq I   Goldman John M  

Clinical Medicine, Vol. 6, Iss. 6, 2006-12 ,pp. : 526-528

Royal College Of Physicians

Access to resources Recommend Favorite

Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases

By Heiko van der Kuip  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 101-112

Adis International

Access to resources Recommend Favorite